Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.
We are now publishing 7x per week according to the following cadence:
Mondays: Stocks
Tuesdays: Biotech
Wednesdays: Podcast
Thursdays: Markets
Fridays: News
Saturdays: Podcast
Sundays: Strategy
We are also publishing unique content on X - be sure to follow up if you are not already @BowTiedBiotech. And to check-out the archive of our work on X you can find it on our website at: BowtiedBiotech.subtack.com/x-articles.
SUBSCRIBE TO THE PODCAST HERE:
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
This week, we’re looking at why the FDA itself may be the most important biotech catalyst right now. Investors still love clean calendars - PDUFA dates, advisory committees, Phase 3 readouts - but the real swing factor is increasingly the agency behind those events. After major staffing disruption, rehiring efforts, leadership changes, and a renewed push toward regulatory flexibility in rare disease and cell and gene therapy, FDA risk is no longer just about whether a drug gets approved. It is about whether the rules feel predictable, whether “alignment” actually means anything, and whether flexibility becomes scientific pragmatism or case-by-case chaos. For biotech investors, that makes the regulator not just the referee, but the trade.
📣🎙️ TODAY’S PODCAST:
[ 01:12 ] Predictability evaporates
[ 02:39 ] PDUFA 7 machine
[ 03:35 ] Institutional trauma arrives
[ 04:50 ] Brain drain hits biotech
[ 06:21 ] Flexibility becomes the trap
[ 08:06 ] Compassion meets weak data
[ 10:01 ] Biopharma reset begins
[ 12:29 ] Risk playbook changes
[ 19:24 ] Moving target reality
CONCLUSION
We hope you are enjoying our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
